RFCA
RCKT icon

R&F Capital Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

R&F Capital Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$78K Buy
+9,778
New +$65.8K 0.02% 629

Other funds holding RCKT

RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FO
FT Options Chicago, Illinois $66.4M AUM 18.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

R&F Capital Advisors's RCKT Position: Q1 2017 in Review

R&F Capital Advisors opened a new position in Rocket Pharmaceuticals (RCKT) in Q1 2017: 9,778 shares worth $78K. The stake represents 0.02% of the portfolio and ranks #629 among its holdings.

67 funds tracked by Wall St. Rank hold RCKT as of Q1 2017.

  • R&F Capital Advisors held 9,778 shares of Rocket Pharmaceuticals worth $78K as of Q1 2017.
  • Rocket Pharmaceuticals was a new R&F Capital Advisors position in Q1 2017.
  • Rocket Pharmaceuticals made up 0.02% of R&F Capital Advisors's portfolio in Q1 2017, its #629 holding.
  • 67 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.